A company still losing money with shrinking sales, with high risk.
Going well
Sales up 29% last year
Watch out for
Sales down 77% in the latest quarter vs a year ago
Late quarterly report notice
Less than a month of cash left at its current burn
Money moves
No insider buying or selling in the last 30 days
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$2.16-2.3% that day
Company value
$7M
Share price times all shares
Price vs sales
0.82x
No profit over the last year, so this compares value with sales instead
Cash vs value
37%
A big cushion: cash is a large part of what the company is worth
Debt vs value
355%
Owes more than the whole company is worth
From MEDS's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 10 quarters, from SEC filings
Sales, Jun '26
$1.8M-77% vs a year earlier
Mar '24Tap a barJun '26
Last 12 months: $8.0M, down 78% from the 12 months before.
What the price assumes
Your guesses, our math
Move the sliders to your own view of MEDS. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).
Sales in 5 years$5M
Profit in 5 years$0M
Price these guesses point to$2.32+7.4% vs $2.16 todayAbout +1.4% a year, before dividends
What today's price needs: with a 10% margin and a 15x P/E, sales could shrink about 11% a year for 5 years and still match today's price.
Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.
The checklist Warren Buffett-style investors use. Annual numbers for 2025.
0/4Weak
MissDebt under half of equityNot relying on borrowed money.Owes more than it owns
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-433.9%
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$10.9M
MissGross margin 40%+Pricing power: sells for well above what it costs to make.-27.5%
Revenue
$23.3M
+28.7% vs prior year
Total debt
$23.5M
Current ratio
0.09x
short-term assets / bills due
Free cash flow
-$10.9M
-46.5% of revenue
From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, profitable every year, share count not growing. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026
Reported Aug 18
Revenue
$1.8M
-77.2% YoY
EPS
-$7.13
vs -$216.00
Op. margin
-412.7%
-342.1 pts
Gross margin
10.2%
+3.7 pts
Free cash flow
-$2.9M
Share count
+8236.0%
vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trend
No trades to chart yet.
Filing buzz
Last 7 days vs normal
43/ 100
This week
1
Normal week
1.3
vs normal
0.8x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Newly held
Institutions held almost none of it the quarter before (new listing, spin-off or ticker change), so there's no fair percent change yet. 9 bought, 0 sold.
Shares held by institutions52K
Sep '24Jun '26
Safety check
From SEC filings
Cash runwayAt last year's cash burn
3 months
Debt to equityLatest balance sheet: debt compared with what owners have
Owes more than it owns
Shares outstandingLatest reported
3M
Why high risk
Losing money, losses are large next to sales
About 3 months of cash left at its current burn
Owes more than it owns (negative equity)
Bills due within a year exceed short-term assets
6 offering filings in 6 months (may sell new shares)
Exchange listing notice (a delisting warning or a move to another exchange)
Late quarterly report notice
Auditor change
Earnings reports
Last 4
Next reportAround Nov 19 (est.)Estimated from the same quarter last year
Results filedAug 18
Results filedMay 19
Results filedNov 20, 2025
Results filedAug 22, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days